Fabry disease is inherited as an X-linked disorder secondary to deficiency of ␣-galactosidase A, resulting in abnormal metabolism of substances containing ␣-D-galactosyl moieties. As a consequence, a multisystem disorder develops, culminating in strokes, progressive renal, and cardiac dysfunction. Signs and symptoms of Fabry disease become manifest in childhood, but diagnosis is often delayed. Thirteen children with Fabry disease (age range, 6.5-17 years) were studied as part of a 6-month open-label study of enzyme replacement therapy (ERT) with agalsidase alfa. Paired serum samples were drawn at the start of the study and after 6 months of ERT. Global protein changes in paired samples were compared by using differential stable isotope labeling of peptide lysine residues with O-methylisourea and subsequent nanoHPLCtandem MS. Statistically significant decreases were observed for five proteins following ERT: ␣2-HS glycoprotein, vitamin D-binding protein, transferrin, Ig-␣-2 C chain, and ␣-2-antiplasmin. The presence of low levels of ␣-2-antiplasmin and plasminogen was confirmed by alternate means in 34 consecutive patients, including four of five ERT-naïve subjects. Decreased ␣-2-antiplasmin was associated with a parallel increase in circulating VEGF. Soluble VEGF receptor-2 was significantly elevated in plasma of patients compared with pediatric controls and decreased with ERT. These results suggest previously unknown abnormalities of fibrinolysis and angiogenesis factors in Fabry disease. We demonstrated the feasibility of identifying treatment-specific alterations in a small number of subjects that point to previously unsuspected diseaserelated biological abnormalities.
F
abry disease is an X-linked disorder (OMIM accession no. 301500), originally described independently by Fabry and Anderson in 1898 (1, 2) . It is caused by a deficiency of the lysosomal enzyme ␣-galactosidase A, resulting in reduced and altered catabolism of ␣-D-galactosyl-containing compounds (3) . The enzyme deficiency results in intracellular accumulation of glycosphingolipids, particularly globotriaosylceramide, leading to cellular dysfunction and eventual significant morbidity due predominantly to renal impairment, stroke and cardiac involvement (4) . Recent work indicates significant functional abnormalities of vasomotion and not solely an obstructive vasculopathy secondary to the mechanical burden of lipid storage. Instead, evidence suggests the vasculopathy consists of impairment of the nitric oxide (NO) pathway, probably because of excess superoxide production resulting in the formation of peroxynitrite and other reactive nitrogen species capable of causing oxidative damage, as evidenced by nitration of protein tyrosine residues (5) . These abnormalities were found in the cerebral circulation and dermal vasculature of patients with Fabry disease (5) (6) (7) (8) . A number of these abnormalities were at least partially corrected by enzyme replacement therapy (ERT) with agalsidase alfa in the form of biweekly infusions (9, 10) . In general, the beneficial effects of ERT in advanced Fabry disease have been modest. There is some improvement in sweating, pain, peripheral nerve function, and probably slowing of the progression of the renal disease (11) . However, there is no clear reduction in the vasculopathic or cardiac complications (11) . There is, therefore, a need to better understand the mechanism of the disease and to develop valid pathophysiological markers that will serve as indicators of disease severity, prognosis, and the effect of specific therapies.
In the absence of specific targets or processes, mass spectrometry-based proteomics offers an unbiased high-content approach to identifying disease-associated compositional changes (12) . However, one of the challenges of such approaches is maintaining consistency in the analysis of complex mixtures. One approach to reducing this problem has been to differentially label the comparator protein or peptide mixtures with stable isotopes, such that consistent mass differences are introduced into selected amino acid residues (13, 14) . The peptides are then combined to reduce the risk of differential losses during subsequent separation and analysis. The mass differences introduced by the isotope tags can be readily resolved by mass spectrometry and the information used to identify the proteins of origin and define their relative abundance in the samples. The conversion of lysine residues to homoarginine after reaction with O-methylisourea provides an economical and efficient means of introducing isotope labels into peptides (15) . This reaction has the added advantage that the conversion to homoarginine increases the propensity of lysine-containing peptides, the ionization of which facilitates protein identification.
In the current study, we used initiation of treatment with agalsidase alfa in ERT-naïve pediatric patients as a method of altering the Fabry disease state. Our hypothesis was that by altering Fabry disease with a specific treatment and by using the patients as their paired controls, we would be able to define disease-related alterations by using O-methylisourea-based differential isotope labeling with tandem MS (MS/MS).
Results
The intent of this study was to identify proteins that differed in their relative abundance in the same patient at baseline (B), i.e., before treatment and after 6 months of ERT (T). To facilitate this analysis equal volumes of B and T serum from each patient were depleted of high-abundance proteins, digested and labeled with the heavy (T) or light (B) forms of O-methylisourea. The samples were combined and separated by multidimensional chromatography before MS analysis.
The introduction of the light and heavy forms of O-methylisourea results in an increase in mass of ϩ42.02 and ϩ45.02 Da, respectively, which means there is a net difference of 3 Da per lysine residue between identical pairs of differentially labeled peptides. Chromatographically, these peptides behave identically, but they can be resolved in the mass spectrometer (Fig. 1A) . A selected parent ion and its potential alternatively labeled counterpart were selected for fragmentation and MS/MS analysis (Fig. 1B) . The resulting fragment y ions and their relative intensities provided the basis for determining peptide sequence and comparison of abundance between the two samples (Fig. 1C) . With this approach, the identities of both parent ions are confirmed. Just as multiple peptide identifications can contribute to identification of a single protein, so the ratios for each of the peptides can provide an averaged ratio with a measure of the variability of the individual peptides [supporting information (SI) Fig. 3] .
A comparison of the relative abundance of 50 proteins identified in at least 5 of 13 patients was examined by comparing the intensities of the fragment peaks observed in the spectra (Table  1) . Alterations of protein levels in serum samples of treated and untreated patients are displayed as a difference of two ratios. If the level of a protein is unaltered, the heavy:light ratio (treated:baseline) is expected to have a value close to 1.0. If this is subtracted from the actual measured ratio, a small difference between these ratios indicates equality between the treated and baseline states, whereas a negative value indicates a decrease in abundance relative to the baseline levels. Conversely, a value Ͼ0 (i.e., a positive value) indicates an increase relative to baseline, providing an indication of the relative abundance of a given protein in the two samples, not a quantitative measurement.
The ratios of these proteins were tested with a nonparametric one-sample Wilcoxon test to quantify the significance of the mean difference ratio, resulting in the identification of five proteins that had undergone treatment-related alterations (TRA) after infusions of agalsidase alfa: ␣-2-antiplasmin precursor, ␦ ϭ Ϫ0.34, P ϭ 0.03125; transferrin (serotransferrin precursor), ␦ ϭ Ϫ0.16, P ϭ 0.03018; ␣-2-HS-glycoprotein precursor (Fetuin-A), ␦ ϭ Ϫ0.21, P ϭ 0.0143; vitamin D-binding protein precursor, ␦ ϭ Ϫ0.14, P ϭ 0.02106; and Ig-␣-2 chain C-region, ␦ ϭ Ϫ0.24, P ϭ 0.01709. Notably, four of these proteins were detected in all 13 patients.
Protein Analysis by Alternative Techniques. Transferrin. Median patient transferrin in stored serum samples at baseline was 253 mg/dl (range 201-267) and 214 mg/dl (range 147-280) after 6 months of ERT. Transferrin levels in three patients increased (two boys and one girl), although they decreased in the other 10. At the 6-month time point, transferrin was low compared with the normal laboratory range (204-345 mg/dl) and age-matched concurrent controls (266 Ϯ 26 mg/dl, n ϭ 16, P ϭ 0.01). However, after subsequent months of ERT, serum transferrin levels drifted toward the normal range in most patients but remained low in some. Ig-␣-2 chain C-region. The significant result for Ig-␣ in MS/MS analysis of Ig led us to test all three Ig classes. We tested Ig levels on the prospectively stored serum samples from baseline and 6 months. The mean IgA level was 234 Ϯ 94 mg/dl at baseline and 204 Ϯ 115 mg/dl at 6 months of ERT (normal range 91-499 mg/dl, P ϭ 0.2). Ten patients had a decrease, and three had an increase in IgA values. Mean IgG level was 1,157 Ϯ 168 mg/dl at baseline and 1,007 Ϯ 189 mg/dl at 6 months (normal range 642-1,730 mg/dl, P ϭ 0.01); There was no significant change in IgM levels. All patients had normal Ig values at both time points. ␣-2-Antiplasmin. The standard chromogenic method for measuring ␣-2-antiplasmin requires a blood sample by using a citrate-based anticoagulant (16) . No ELISA-based method for ␣-2-antiplasmin determination is available. Thus, we could not measure retrospectively the MS/MS ␣-2-antiplasmin levels at the baseline and 6 months of ERT time points. Instead, we assayed ␣-2-antiplasmin levels in 8 of the 13 children who had been on ERT for at least 2 years as well as 21 other nonselected mostly adult Fabry patients on long-term ERT (on both agalsidase alfa and beta) and four ERT-naïve patients. Overall, the mean level of ␣-2-antiplasmin in these 34 consecutive Fabry patients aged 10-55 years was 85 Ϯ 12% vs. normal laboratory mean of 105; range 82-123%, n ϭ 56 (P Ͻ 0.0001; Fig. 2A ). Thirteen of 29 patients on ERT (45%), including three (two males and one female) of the original cohort of children, had below-normal ␣-2-antiplasmin levels, median 75%, range 63-80%. ␣-2-Antiplasmin in four of five ERT-naïve patients had below-normal levels (range 73-77%, Fig. 2 A) . Because the low levels of ␣-2-antiplasmin are likely the result of overconsumption of this protein, we assayed the same plasma samples in the patients with low or borderline ␣-2-antiplasmin for plasminogen. All patients with low ␣-2-antiplasmin levels also had below-normal plasminogen levels (median 54%, range 49-69%; normal range, 77-124%). There was a significant correlation between ␣-2-antiplasmin and plasminogen levels values in this group (r ϭ 0.59, P ϭ 0.02) (Fig. 2B ). D-dimer and fibrinogen degradation products were not elevated in the patients with low ␣-2-antiplasmin levels (not shown). Because ␣-2-antiplasmin is known to regulate the amount of VEGF, we measured it and VEGF-receptor 2 (VEGFR-2) in patients' plasma (17) . We found that the seven patients who had a significant reduction of ␣-2-antiplasmin had on average 31% increase in circulating VEGF. Soluble VEGFR-2 was significantly increased in the 13 children with Fabry disease compared with pediatric controls (11,729 Ϯ 1,222 pg/ml vs. 9,352 Ϯ 1,661; P Ͻ 0.0001) followed by a reduction at 6 months of ERT (10,697 Ϯ 1,556 pg/ml; P ϭ 0.07) and a further reduction at 2.5 years (10,303 Ϯ 968 pg/ml; P ϭ 0.02).
Discussion
The present study examines changes in the serum proteome after 6 months of ERT with agalsidase alfa in ERT-naïve pediatric patients with Fabry disease by using a stable isotope technique and MS/MS. Children with Fabry disease generally have not developed the secondary vascular, cardiac, and renal complications typical of adult patients and therefore present an opportunity to examine the primary biology of this disease (18) . Following a rigorous identification threshold, a restriction of the analysis to identified proteins present in more than five patients was imposed so that potential ERT (Fabry disease-related) effects could be determined. Five significant TRA in the serum proteome were found. The term TRA is based on the assumption that ERT, being a specific intervention that addresses the primary defect in this disorder, induces changes in circulating proteins that are directly related to a deficiency of this specific enzyme. However, we cannot at this time exclude that some of the observed changes are due to nonspecific effects of infusing a ''foreign'' protein because the majority of the males in this study had no detectable enzyme in their serum. However, all but one of the patients had no antiagalsidase antibodies at any time, and nonspecific effects would be expected to increase inflammationrelated molecules such as transferrin, which actually decreased with ERT. This method of identifying TRA in which each patient acts as his/her own control may offer an advantage over a populationbased comparison of untreated Fabry patients with healthy controls. Indeed, a large MS-based proteomic study comparing plasma of adult Fabry patients with healthy controls failed to yield protein abnormalities that are related to the vasculopathy of this disease (J. M. F. G. Aerts, personal communication). Changes in transferrin, Ig-␣-2 C chain, and ␣-2-antiplasmin levels were validated independently. Ongoing analysis is being carried out for vitamin D-binding protein and Fetuin-A by alternative protein identification techniques. For the TRA involving transferrin, ERT resulted in a significant, although transient for some, decrease in serum levels. We might speculate that the decline represents relatively excessive tissue levels of free iron in Fabry disease patients due to abnormal cellular turnover or a level of chronic inflammation. Greater chelation of free iron by higher transferrin levels would tend to reduce the amount of free iron available to catalyze the generation of reactive oxygen free radicals by the Fenton reaction. An alternative explanation is that there may be abnormal glycosphingolipid recycling in Fabry disease resulting in impaired transferrin recycling through the rab4 pathway. A similar abnormality has been described in Niemann-Pick A and C disease (19) . Such abnormal cellular recycling of transferrin could then result in an increase in the size of the serum transferrin pool.
Ig-␣-2 chain C-region was found as a TRA, an indicator of reduction in IgA. This finding led to the identification of a reduction in IgG that was also suggested by the presence of a nonsignificant reduction in Ig-chain C and in Ig-chain C-regions (Table 1) . Interestingly, the only patient who had an increase in IgG transiently developed antibodies to agalsidase alfa. There have been a number of case reports of immune disorders occurring in patients with Fabry disease such as IgA nephropathy (20) , nephropathy due to systemic lupus erythematosus (21), crescentic glomerulonephritis (22) , and chronic aseptic meningitis with an inflammatory syndrome (23) . The mechanism of Ig reduction is not clear, but it is unlikely to be an immune response. It is of interest that levels of this protein diminished with ERT, suggesting a possible antiinflammatory effect.
Elevated levels of vitamin D-binding protein have been associated with endothelial shear stress and other physiological disturbances (24, 25) . As previously noted, Fabry disease has a significant vasculopathic component, so that the TRA of vitamin D-binding protein suggests that ERT with agalsidase alfa is at least partially reducing endothelial stress. Proliferative properties of vitamin D-binding protein on vascular smooth muscle cells could explain the increased arterial intimal-medial thickness ratio and the myocardial hypertrophy reported in Fabry patients, as well as the growth-promoting effect of plasma obtained from untreated Fabry patients on cultured vascular smooth muscle cells and myocytes (26, 27) .
Low levels of Fetuin-A have been associated with vascular calcification (28) (29) (30) (31) . It is possible that Fetuin-A could be relatively elevated in untreated patients with Fabry disease as a protective response to an increased risk of vascular calcification (32, 33) .
␣-2-Antiplasmin is a known inhibitor of plasmin and part of the serpin family (serine protease inhibitors) (34, 35) . It is the key counterregulatory molecule that controls plasmin-mediated fibrinolysis. The combined and positively correlated reduction of ␣-2-antiplasmin and plasminogen is pathognomonic of an overconsumption of these factors (36) . These abnormalities were also found in ERT-naïve patients, suggesting that this abnormality is part of the Fabry disease phenotype. A synthetic abnormality of fibrinolytic factors can be ruled out by the absence of liver dysfunction in Fabry disease and the lack of correlation between ␣-2-antiplasmin and serum albumin levels (data not shown). We recently found that ERT led to overexpression of serpinf1, the ␣-2-antiplasmin gene, in the aorta of the Fabry disease mouse model (P. A. Ferreira, A. Elkahloun, L. M. Lix, R.O.B., R.S., and E.G., unpublished work). Plasminogen activator inhibitor-1 is another regulator of fibrinolysis that has been determined to be abnormal in Fabry disease, suggesting further independent corroboration for an abnormality of fibrinolysis in Fabry disease (37, 38) . The normal fibrinogen degradation products suggest that an endothelial dysfunction results in either low-grade secretion of tissue plasminogen activator (tPA) or enhanced plasminogen activation on the surface of the endothelial cell by urokinase-type plasminogen activator. The latter hypothesis is attractive because gangliosides play an important role in the binding of plasminogen to the cell surface (39) . Globotriaosylceramide is normally present on the cell surface and is elevated in some disease states (40) . Therefore, an increase content of ␣-D-galactosyl-containing sphingolipids in Fabry disease in the cell membrane (R.S., unpublished data) may cause enhanced activation of plasminogen to plasmin by u-PA. ␣-2-Antiplasmin, plasminogen, and tPA concentrations in the blood should be measured in a larger number of ERT-naïve patients. In addition, binding and activation of plasminogen on the surface of vascular endothelial cells should be studied.
The challenges of this study should not be underestimated (41) . From a proteomics viewpoint, serum or plasma samples are highly complex, containing Ϸ10 orders of magnitude differences in protein concentration, necessitating extensive preprocessing of the samples. Significant intra-and interindividual alterations also occur in the human plasma proteome. These were minimized in the present study by pairing the samples for each patient, allowing extraction of a TRA with a surprisingly small number of patient samples. Such patient variation can also be compounded by nonstandard sample collection and processing, whereas the very nature of the MS with the formation of fragmentation products results, at least theoretically, in some potential for incomplete sampling of the serum proteome.
The main limitation of our study is that the technique we used allows us to identify changes in protein levels but not the absolute serum concentrations. Therefore, an understanding of how these changes in proteomics relate to the underlying pathophysiology of Fabry disease can be achieved only by measuring the levels of these specific proteins in ERT-naïve patients (i.e., in the absence of or before the start of ERT). Nevertheless, the present study of serum proteome has allowed further insight into the pathophysiology of Fabry disease with particular relevance for potential mechanisms of Fabry vasculopathy. It utilizes the partially corrective response of agalsidase alfa to perturb the Fabry state sufficiently so that with the use of high-precision proteomics and stable isotopes, true biological signals are determined. The TRA defined in the present study generated disease-related alterations and insight into the mechanisms responsible for the vasculopathy of Fabry disease. Furthermore, these results produce hypotheses that can be tested in future studies. Similar proteomic approaches might be used to gain understanding of other biological disorders (42) .
Methods
Study Design and Subjects. Thirteen patients with Fabry disease (12 boys and one girl) in the National Institutes of Health (NIH) cohort of a multicenter multinational pediatric trial of agalsidase alfa were entered into the MS/MS arm of the current study, i.e., the entire the NIH cohort of the above-mentioned trial. Age ranged from 6.5 to 18 years; other cohort characteristics are described elsewhere (43) . The study was reviewed and approved by the institutional review board of the National Institute of Neurological Disorders and Stroke. All subjects and their parents or legal guardians gave written informed consent before enrollment in the study. Eleven of the patients had mutations associated with no residual enzyme activity, whereas two patients had 2-5% ␣-galactosidase A activity because of the R112H mutation. Each patient was part of an open-label 26-week trial of agalsidase alfa administered in a biweekly dose of 0.2 mg/kg (Replagal; Shire Human Genetic Therapies, Cambridge, MA). Serum samples were taken at baseline before initiation of ERT and at the end of the study. To ensure preanalytic consistency, all samples were drawn between 7:00 and 9:00 a.m. after an overnight fast. The 6-month samples were drawn 14 days after the last agalsidase alfa infusion. The samples were coded and stored at Ϫ80°C until analysis. All MS/MS sample analysis was performed in a blinded fashion.
Differential Isotope Labeling and HPLC MS/MS Analysis and Statistics.
Both light (C 12 , 2N 14 ) and heavy (C 13 , 2N 15 ) forms of the labeling reagent, O-methylisourea, were synthesized according to the method described by Brancia et al. (15) by using normal (Sigma, St. Louis, MO) and C 13 , 2N
15 urea (Cambridge Isotope Laboratories, Andover, MA), respectively, as a starting material.
Serum samples were sequentially passed through protein A and Cibacron blue columns to remove IgG and albumin, respectively. The samples were then reduced, alkylated with iodoacetamide (concentration, time), and digested with tryspin (concentration time). The baseline samples were treated with O-methyl-C 12 , N 14 -isourea, whereas the 6-month, ERT samples were modified with O-methyl-C 13 , 2N 15 -isourea (15) . Preliminary studies determined that these conditions result in quantitative conversion of all lysine residues into homoarginine resulting in mass difference ϩ42.02 and ϩ45.02 Da for light and heavy labels, respectively. Because arginine-containing peptides are not labeled under these conditions, only data from lysinecontaining peptides contribute to the comparative quantitation. However, both Arg-and Lys-containing peptides can contribute to the MS/MS identification of a protein.
After isotopic labeling, paired patient samples were mixed, purified by using C18 sorbent, and fractionated on a cationexchange column (1 ϫ 100-mm PolySULFOETHYL A; PolyLC, Columbia, MD) with a linear ammonium formate gradient. Twenty-one peptide-containing cation-exchange fractions were collected in each case and analyzed by using online nano-liquid crystallography (nanoLC) MS/MS. Linear water/acetonitrile gradient (5-40% in 60 min, with 0.1% formic and 0.005% hexafluorobutyric acids as modifiers) was applied at the final fractionation step. Peptides were separated online by nanoLC (Dionex, Sunnyvale, CA) by using a 75-m ϫ 250-mm C18 column and analyzed by electrospray ionization MS/MS with a QStar Pulsar mass spectrometer (MDS SCIEX/Applied Biosystems, Concord, ON, Canada). The cycle used for MS/MS analysis was 10 sec per cycle, standard scan conditions. Each cycle consisted of a 1 sec of MS survey scan and three 3-sec MS/MS product ion scans on most intense peaks.
Equal volumes of baseline and treated sera were processed in identical fashion before mixing and fractionation to ensure that any quantitative differences at the protein level would be converted into differences in peptide concentrations. Both light and heavy labeled Lys-containing peptides possess identical chemical properties, which guarantees their coelution in both chromatographic dimensions used. Therefore, the ratio of the intensities for peak clusters with masses separated by 3 Da (1.5 Da for doubly charged ions and 1.0 Da for triply charged ions) on each MS survey scan represents differences in protein abundance for baseline and ERT samples (Fig. 1 A) . The use of a wide mass selection window (Ϯ4 Da) permitted the capture of both parent ions at the quadrupole section of the mass spectrometer and subsequent fragmentation in the collision cell (Fig. 1 A) . Both b and y ions are present in resultant MS/MS spectra ( Fig. 1 B and C) . Because singly charged y ions carry the isotopic tag at the C termini of peptides, they are separated by 3 Da on MS/MS spectra. The information encrypted in m/z values of fragment ions was used for protein identification, whereas the ratios of peak intensities for y ion pair for protein quantitation.
Protein Identification and Estimation of Relative Abundance. A normal tandem search was done by using the Global Proteome Machine Organization proteomics database (www.thegpm.org), with the parameters set so that the engine looks for complete lysine modifications of either the light (ϩ42.02 at K) or heavy (ϩ45.02 at K) tag and partial modifications of ϩ3 at K or Ϫ3 at K, respectively, to capture the alternate tag when combined with the complete modification. The spectra supporting hypothetical tryptic peptides with charge states of ϩ2 and cleavage at a lysine residue are selected for further examination.
For each peptide in the list, the sequence was examined against the observed spectrum, and for each hypothetical y ion fragment of the sequence, the spectra were searched for the intensities of fragments of two masses: the mass of the fragment ϩ42.02 Da and the mass of the fragment ϩ45.02 Da. All other selected modifications were also taken into account. If (and only if) both mass/ intensity pairs are found for a fragment, the intensities are added to the light and heavy sums for the peptide. The ratio of the final heavy and light sums for the spectrum is the ratio recorded on the peptide display and added as one of the observed ratios accumulated for the protein and model displays. For protein and model display, the number of observed ratios and the mean and standard deviation of the ratios are shown. Spectra for which ratios could not be calculated do not enter into the statistics.
Protein identification in the current study was performed by using programs available at the Global Proteome Machine Organization project (www.thegpm.org). The data were searched against the Homo sapiens National Center for Biotechnology Information (ENSEMBL) database to derive an expectation value (SI Fig. 3 ). This is quoted as log() and represents the number of times an assignment of equal quality could be expected to occur at random, given the collection of spectra and protein sequences used to make the assignment. In the present study, we used a log() value of Ϫ3, so that the identifications cited have a maximum Յ1 in 1,000 of occurring by chance. Proteins that were identified in fewer than five patients were ignored because the goal of the current analysis is to derive disease-specific and not patient-specific information. A total of 61 proteins were identified as occurring in five patients or more. A visual display of this frequency plot is seen in SI Fig. 4 , together with a color intensity display of log().
As mentioned above, even in the case of confident protein identification, isotope ratios are not always available. This difficulty occurs if Lys-containing peptides are not observed for a given protein as a result of either lack of such peptide in a protein or the failure to detect them because they are too small or too big to be separated and confidently identified. Included in this analysis are the names of the identified proteins, together with the mean difference of the isotope ratio from 1.0 for all Fabry patients contributing to that protein signal. The ratio difference from 1.0 was tested for statistical significance by using the nonparametric one-sample Wilcoxon test with the null hypothesis that the isotope ratio equals 1.0 (44) . Several proteins were significant at a level of P Ͻ 0.05.
Protein Analysis by Alternative Techniques. To validate these findings, proteins identified through MS/MS were assayed with a second independent method in an extended population of patients and controls.
Transferrin. Serum samples from patients with Fabry disease and controls were assayed by using a immunoturbidimetric method on a Synchron LX-20 analyzer (Beckman Coulter, Brea, CA) (45).
Plasminogen and ␣-2-Antiplasmin. Plasminogen and ␣-2-antiplasmin activities were measured with an nSTA COAG instrument manufactured by American Diagnostica (Parsippany, NJ).
VEGF and VEGF Receptor 2. VEGF and VEGF receptor 2 were both measured by ELISA in patient and control plasma by using a Quantikine ELISA kit (R & D Systems, Minneapolis, MN).
